FDA granted accelerated approval to Genentech's Tecentriq (atezolizumab) for the initial treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.
FDA granted Breakthrough Therapy designation to Novartis's CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma who have failed two or more prior therapies.
Health Canada approved via priority review Janssen's Darzalex (daratumumab), in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
The National Coalition for Cancer Survivorship launched a nationwide competition for the 2017 Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care, an opportunity for patients and survivors to recognize exceptional providers who are transforming cancer care.
Luis Diaz was named the head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering Cancer Center as David Spriggs steps down after nearly 13 years.
MD Anderson Cancer Center and Lion Biotechnologies Inc, a biotechnology company developing cancer immunotherapies based on tumor-infiltrating lymphocyte technology, announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian, various sarcomas, and pancreatic cancers.
The National Comprehensive Cancer Network added recommendations from an additional nine NCCN Clinical Practice Guidelines in Oncology to its NCCN Radiation Therapy Compendium:
The American Health Care Act would have a negative impact on affordability and patient access to cancer screening and treatment, according to a survey conducted by the National Comprehensive Cancer Network.
Up to 480 March for Science rallies are scheduled to take place on Earth Day, April 22 in almost 500 cities in at least 37 countries, according to the movement's organizers.
Enrolling less homogeneous patient groups in clinical trials while maintaining safety may lead to a more accurate description of a drug's safety and efficacy, FDA officials wrote in an article published April 20 in the New England Journal of Medicine.
